IGC Pharma, Inc. (NASDAQ:IGC)

BRIEF

published on 12/20/2024 at 01:05, 1 day 17 hours ago

IGC Pharma to Engage in BIO Partnering @ JPM with Key Stakeholders

Healthcare Strategy IGC Pharma BIO Partnering JPM Conference Pharmaceutical Meetings
PRESS RELEASE

published on 12/20/2024 at 01:00, 1 day 17 hours ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
IGC Pharma, Inc. will participate in BIO Partnering @ JPM alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. The management team will showcase recent partnerships and achievements

Clinical-stage Biotechnology IGC Pharma Alzheimer's Treatment J.P. Morgan Healthcare Conference BIO Partnering @ JPM
BRIEF

published on 12/02/2024 at 14:35, 19 days 4 hours ago

IGC Pharma Advances Alzheimer's Treatment Research

Clinical Research IGC Pharma Alzheimer's Treatment IGC-AD1 Trials Cognitive Improvement
PRESS RELEASE

published on 12/02/2024 at 14:30, 19 days 4 hours ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
IGC Pharma, Inc. expands clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease, to evaluate disease-modifying potential targeting amyloid plaque and tau tangles

Clinical Research Alzheimer's Disease IGC Pharma IGC-AD1 Disease-modifying Therapy
BRIEF

published on 11/14/2024 at 14:35, 1 month 7 days ago

IGC Pharma Reports Financial and Strategic Milestones for Q2 FY2025

Financial Results Revenue Growth IGC Pharma Alzheimer's Treatments R&D Advancements
PRESS RELEASE

published on 11/14/2024 at 14:30, 1 month 7 days ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 month 15 days ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 month 15 days ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 2 months 4 days ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 2 months 4 days ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy

Published on 12/21/2024 at 01:30, 17 hours 29 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 29 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 54 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 18 hours 59 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 29 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 18 hours 8 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 14 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 48 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 6 hours 41 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 4 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News